Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Russell

Neurology New Haven, CT Medical Doctor

NPI 1548241839 CMS profile 251083

60 Temple St, Suite 8B, New Haven, CT 06510

Open in the dashboard

General payments

$207,764

264 records reported · program years 2019–2025

Research payments

$28,352

Paid to them · 16 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$30,956,441 paid to institutions, not to them · program years 2019–2025

Through program year 2025, David Russell of New Haven, CT is reported in the CMS Open Payments database as having received $207,764 across 264 general payments and $28,352 in research payments paid to them. Separately, studies naming them as principal investigator received $30,956,441 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $40,929 46
2024 General $67,646 75
2024 Research $5,636 1
2023 General $42,703 54
2023 Research $787 2
2022 General $14,949 20
2022 Research $5,615 4
2021 General $16,201 20
2021 Research $2,671 2
2020 General $3,743 6
2020 Research $8,296 5
2019 General $21,593 43
2019 Research $5,347 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Russell
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to David Russell were reported at $40,929. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year David Russell Neurology median Middle half National median
2019 $21,593 $474 $118–$2,177 $163
2020 $3,743 $367 $82–$2,309 $114
2021 $16,201 $438 $104–$2,547 $132
2022 $14,949 $442 $103–$2,388 $149
2023 $42,703 $464 $119–$2,312 $160
2024 $67,646 $468 $119–$2,323 $164
2025 $40,929 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Eisai Inc. $95,502 102 payments
  2. Neurocrine Biosciences, Inc. $43,387 63 payments
  3. Lilly USA, LLC $30,215 27 payments
  4. Acorda Therapeutics, Inc $12,502 20 payments
  5. Ge Healthcare $8,908 15 payments
  6. Biogen, Inc. $4,540 16 payments
  7. Ucb SA $3,684 4 payments
  8. Teva Pharmaceuticals USA, Inc. $3,133 4 payments
  9. Adamas Pharmaceuticals, Inc. $1,948 3 payments
  10. Amneal Pharmaceuticals LLC $1,668 2 payments
  11. Other $2,277 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $96,030 48 payments
  2. Consulting Fee $46,231 19 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $38,081 27 payments
  4. Travel and Lodging $17,764 60 payments
  5. Food and Beverage $6,120 107 payments
  6. Honoraria $1,870 1 payment
  7. Education $1,668 2 payments
Products named General payments · program years 2019–2025
  1. Leqembi $87,153 95 payments
  2. KISUNLA $28,766 22 payments
  3. INGREZZA Neuropsychiatry $18,768 31 payments
  4. INBRIJA $12,238 15 payments
  5. ONGENTYS Neurology $8,816 9 payments
  6. Ongentys Neuropsychiatry $8,778 10 payments
  7. INGREZZA Neurology $4,594 10 payments
  8. AUSTEDO $3,133 4 payments
  9. GOCOVRI $1,948 3 payments
  10. ONGENTYS 50MG CAPSULES 30 $1,112 1 payment
  11. Other $917 7 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $24,426 11 payments
  2. Biogen, Inc. $2,643 1 payment
  3. F. Hoffmann-La Roche AG $711 3 payments
  4. Neurocrine Biosciences, Inc. $572 1 payment

Records

280 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record